Bianchi Francesco Paolo, Donghia Rossella, Tatoli Rossella, Bonfiglio Caterina
Epidemiology Unit, Bari Policlinico General Hospital, 70124 Bari, Italy.
National Institute of Gastroenterology, IRCCS S. De Bellis, Research Hospital, 70013 Castellana Grotte, Italy.
Vaccines (Basel). 2023 Sep 25;11(10):1523. doi: 10.3390/vaccines11101523.
Individuals with Inflammatory Bowel Disease (IBD) are characterized by an increased vulnerability to complications stemming from infectious diseases. While these patients do not inherently face a heightened risk of SARS-CoV-2 infection compared to the general population, their vulnerability to severe COVID-19 complications and subsequent hospitalization is notably increased. The objective of our study is to quantitatively assess the global coverage of COVID-19 vaccination among individuals with IBD, achieved through a comprehensive meta-analysis and systematic review. Thirteen studies were systematically selected from scientific articles available in the MEDLINE/PubMed, ISI Web of Knowledge, and Scopus databases, spanning from 1 January 2021 to 25 July 2023. The pooled prevalence of COVID-19 vaccine uptake was estimated at 72% (95%CI = 59-83%) for at least one dose, 81% (95%CI = 68-91%) for the complete vaccination regimen, and 71% (95%CI = 46-91%) for the third dose. Analysis of the determinants influencing vaccination uptake revealed several significant associations. These encompassed Caucasian ethnicity, female sex, absence of immunosuppressive therapy, advanced age, prior receipt of the anti-influenza vaccine, absence of a history of COVID-19 infection, and the provision of advice from gastroenterologists, all linked to improved compliance. Our study underscores a noteworthy yet not entirely optimal COVID-19 vaccination coverage among individuals with IBD. A multifaceted approach is warranted to enhance vaccination rates. Within this context, the role of gastroenterologists extends beyond direct patient care, encompassing a pivotal responsibility in preventing complications stemming from post-infectious diseases.
炎症性肠病（IBD）患者的特点是更容易出现由传染病引发的并发症。虽然与普通人群相比，这些患者本身感染SARS-CoV-2的风险并未增加，但他们出现严重COVID-19并发症及随后住院的易感性显著增加。我们研究的目的是通过全面的荟萃分析和系统评价，定量评估IBD患者中COVID-19疫苗接种的全球覆盖率。从MEDLINE/PubMed、ISI Web of Knowledge和Scopus数据库中2021年1月1日至2023年7月25日期间可用的科学文章中系统选取了13项研究。至少接种一剂COVID-19疫苗的合并接种率估计为72%（95%CI = 59-83%），完成全程疫苗接种方案的为81%（95%CI = 68-91%），接种第三剂的为71%（95%CI = 46-91%）。对影响疫苗接种的决定因素进行分析后发现了几个显著关联。这些因素包括白种人、女性、未接受免疫抑制治疗、高龄、先前接种过抗流感疫苗、无COVID-19感染史以及胃肠病学家提供的建议，所有这些都与更好的依从性相关。我们的研究强调了IBD患者中值得注意但并非完全理想的COVID-19疫苗接种覆盖率。需要采取多方面的方法来提高接种率。在此背景下，胃肠病学家的作用不仅限于直接的患者护理，还包括在预防感染后疾病并发症方面的关键责任。
